



## Publication of a shareholder newsletter

**Paris, October 4<sup>th</sup>, 2016** - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announces the publication of a shareholder newsletter that provides an update on the major achievements of the first half of 2016. The Shareholder Newsletter is available on the website at: [www.abivax.com](http://www.abivax.com) (Investors and Investor Presentation).

### About ABIVAX ([www.abivax.com](http://www.abivax.com))

**ABIVAX** is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase II clinical trials and is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action. In addition, ABIVAX is advancing multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue) as well as an immune enhancer, and several of these compounds are planned to enter clinical development within the next 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at [www.abivax.com](http://www.abivax.com).

Follow us on Twitter @ABIVAX

### Contacts

#### Finance

Alain Chevallier  
[Alain.chevallier@abivax.com](mailto:Alain.chevallier@abivax.com)  
+33 1 53 83 08 41

#### Press Relations

**ALIZE RP**  
Caroline Carmagnol/Margaux Pronost  
[abivax@alizerp.com](mailto:abivax@alizerp.com)  
+33 6 64 18 99 59 / +33 1 44 54 36 65

#### Citigate Dewe Rogerson

Antoine Denry/Alexandre Dechaux  
[abivax@citigate.fr](mailto:abivax@citigate.fr)  
+33 1 53 32 84 75

#### LifeSci Advisors

Chris Maggos  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 6254